<SEC-DOCUMENT>0001628280-19-011974.txt : 20190927
<SEC-HEADER>0001628280-19-011974.hdr.sgml : 20190927
<ACCEPTANCE-DATETIME>20190927171659
ACCESSION NUMBER:		0001628280-19-011974
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190927
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20190927
DATE AS OF CHANGE:		20190927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		191122979

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kifetrobanfdagrant.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9bf50678b1374aabb81b6da4de6f14d4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">________________________________</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(D)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):  September 27, 2019 (September 24, 2019)</font></div></td></tr></table></div></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)     </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2525 West End Avenue, Suite 950, Nashville, Tennessee 37203</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(615) 255-0068</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Registrant&#8217;s telephone number, including area code)</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Former name or former address, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times_New_Roman;font-size:10pt;">Trading Symbol</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times_New_Roman;font-size:10pt;">Name of exchanged on which registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, no par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times_New_Roman;font-size:10pt;">CPIX</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times_New_Roman;font-size:10pt;">NASDAQ Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s14ffe8c48bf340809abec610b3438692"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2019, Cumberland announced U.S. Food and Drug Administration ("FDA") Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the FDA has cleared Cumberland&#8217;s application to study ifetroban in DMD patients, 7 years of age and older.  In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support this Phase II DMD clinical study. It&#8217;s the first DMD clinical study approved for FDA Orphan Product Development funding.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DMD is a rare, fatal, genetic neuromuscular disease and is characterized by the progressive loss of muscle which results in deterioration of the skeletal, heart and lung muscles. This deterioration leads to loss of movement and wheelchair dependency. Heart muscle disease is now the leading cause of death in patients with DMD. There is currently no universally effective treatment for the cardiomyopathy associated with DMD, and it remains an unmet need.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ifetroban is a selective and potent thromboxane-prostanoid receptor (TPr) antagonist. Preclinical work on this molecule demonstrated that blocking TPr with ifetroban improves cardiac survival while increasing cardiac output in multiple animal models. These encouraging findings compelled Cumberland to develop a clinical program to evaluate ifetroban for the treatment of DMD cardiomyopathy. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A copy of the press release is furnished as </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexhibitfdagrant.htm"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sf629a2635171418aaf3dafc11b20e842"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:24%;"></td><td style="width:13%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:12%;"></td><td style="width:13%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: September 27, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;"><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pressreleaseexhibitfdagrant.htm"><font style="font-family:inherit;font-size:10pt;">Press release dated September 24, 2019</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseexhibitfdagrant.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3023bd34575747b5a4f1ca10f06ef064"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="cumberlandlogoa03.jpg" alt="cumberlandlogoa03.jpg" style="height:109px;width:484px;"></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS ANNOUNCES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FDA ORPHAN DRUG GRANT AWARD</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FOR NEW PHASE II CLINICAL PROGRAM </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NASHVILLE, TENNESSEE (Tuesday, September&#160;24, 2019) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:12pt;">, a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. Food and Drug Administration (FDA) has cleared Cumberland&#8217;s application to study ifetroban in DMD patients, 7 years of age and older.  In addition, Cumberland has been awarded just over $1 million in funding from the FDA through their Orphan Drug Grant program to support a Phase II DMD clinical study. It&#8217;s the first DMD clinical study approved for FDA Orphan Product Development funding.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">DMD is a rare, fatal, genetic neuromuscular disease and is characterized by the progressive loss of muscle which results in deterioration of the skeletal, heart and lung muscles. This deterioration leads to loss of movement and wheelchair dependency. It affects 1 in 3,500-5,000 male children, making it the most common childhood muscle disease. Heart muscle disease is now the leading cause of death in patients with DMD. There is currently no universally effective treatment for the cardiomyopathy associated with DMD, and it remains an unmet need.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;This new program is an excellent strategic fit for our company given our mission to develop new medicines that address unmet medical needs,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.  &#8220;As ifetroban may uniquely address the heart failure associated with this deadly disease, we very much appreciate the FDA grant support of our novel treatment for these critically ill patients.&#8221;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ifetroban is a selective and potent thromboxane-prostanoid receptor (TPr) antagonist. Preclinical work on this molecule demonstrated that blocking TPr with ifetroban improves cardiac survival while increasing cardiac output in multiple animal models. These encouraging findings compelled Cumberland to develop a clinical program to evaluate ifetroban for the treatment of DMD cardiomyopathy. The new Orphan Drug grant funding will support a Phase II multicenter study evaluating ifetroban for safety and efficacy in the treatment of DMD heart muscle disease while improving the quality of life in children and men with DMD. For more information about enrollment in this clinical trial please email the Company at </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">research@cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Cumberland Pharmaceuticals</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high quality prescription brands to improve patient care. The Company develops, acquires and commercializes brands for the hospital acute care, gastroenterology and oncology market segments. These medical specialties are categorized by moderately concentrated prescriber bases that we believe can be penetrated effectively by targeted sales forces. The Company&#8217;s portfolio of FDA approved brands includes:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acetadote</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of acetaminophen poisoning;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of pain and fever;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Kristalose</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Omeclamox</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">-Pak</font><font style="font-family:inherit;font-size:12pt;">, (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">omeprazole, clarithromycin, amoxicillin</font><font style="font-family:inherit;font-size:12pt;">) for the treatment of Helicobacter pylori (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">) infection and related duodenal ulcer disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vaprisol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ethyol</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;(amifostine) </font><font style="font-family:inherit;font-size:12pt;">Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Totect</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(dexrazoxane hydrochloride) </font><font style="font-family:inherit;font-size:12pt;">Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:12pt;padding-left:17px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vibativ</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">telavancin</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:4px;padding-top:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company&#8217;s website </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:174%;text-align:justify;padding-left:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland has submitted a New Drug Application for the approval of</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;RediTrex</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">TM</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">methotrexate</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company has Phase II clinical programs underway evaluating ifetroban in patients with Systemic Sclerosis (&#8220;SSc&#8221;), the deadliest autoimmune disease and in patients with a severe form of asthma, Aspirin-Exacerbated Respiratory Disease ("AERD"),</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland has also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;).</font></div><div style="line-height:174%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About the FDA Orphan Drug Grant Program</font></div><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. The OOPD evaluates scientific and study data from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. The OOPD also provides incentives for sponsors developing medical products for rare diseases including the Orphan Drug Designation program, the Rare Pediatric Disease Review Priority Voucher program and the Orphan Products Grant Program. The Grant Program provides funding for clinical research aimed at evaluating the safety and efficacy of medical products in rare diseases. Cumberland&#8217;s Phase II study is the first DMD clinical trial approved for FDA OPD funding.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Ifetroban</font></div><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ifetroban is a pharmacological antagonist of the thromboxane A2 / prostaglandin endoperoxide receptor (TPR). Ifetroban exhibits high-affinity for TPRs on platelets, vascular and airway smooth muscle and certain other cell types and lacks agonistic activity. Ifetroban also displays anti-platelet, antivasospastic and antibronchospastic activities and is effective in certain preclinical models of vasospasm, thrombosis, reperfusion injury and endothelial dysfunction, including models that are insensitive to aspirin.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding our intent, belief or expectations. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erin Gull</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeff Bradford</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Bradford Group</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 515-4880</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:174%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandlogoa03.jpg
<TEXT>
begin 644 cumberlandlogoa03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %W!G(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_T4]??]?"9I_O<_E^2/;P7\" 4445Y9WA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XF\4:=X-\/WVM:Q=
MI9:980^;<3R?P+6_7Y_?M@?&[_A8/C'_ (0G29]_AK1)O].DC^Y>WR_\L_\
M<B_]#SUV UV87#_6:G)TZF4I<AQ?Q.^*VI_&SQI_;VH1R6NF6NY-&TJ3_EVB
M;_EJW_35^_\ ='R]C4.FURNG5U6FU]7R>S_=T]D<D3K--KL-+KC]-KL-+KBJ
M&\3K-+KLM-KS'_A.-!TFZ^PW6K1O>_\ /C!NN+A_^V4>7_2NPT/4O%&M1_\
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MM;QS#DVA][#V9^:%Q\$?B1JDG^C^ =<_[;I'%_.2JMQ^R1\7]0CW+X,V;O\
MGMJEHO\ [4K].:*?]J5?(GV)^65Q^PO\9+_S/^)%IL'_ %WU2/\ ]E)K#O/^
M"<_QINONZ;HZ?]Q1?\*_6FBK_MC$>7W,PEA*<^Y^>G[,=OKG[%<GBCPYXNTV
M/5+W5'M[Y/[.O5V(NUU )->]P_MGZ5_RV\+WR+_L74;_ .%><?M6?\EAN_\
ML'6__M2O&Y*\NO6GB*GM)[LZ:=/V,.2&R/KRS_;*\)W$G^E:3K%K_P  B?\
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MD;LC.17Z8YX%3B,+/".U3J.CB(8CX-;"T445RG2%%%% !1110 4444 %%%%
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MKEN*H[P?R-J>-H3^VCZEHK,TW5K'7--@O-/G@O;25-Z3P/O1U]B*TZ\_;<[
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MIBZD_(WY3G/"O@GP]X+M?LN@Z+8Z);_\\[&!8O\ T&NCHHKB- HHHH ****
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ML<G]D:W_ !Z==O\ ._\ US;I)^'/M7J- !1110 4444 %%%% !1110 4444
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M _\ !=#_ /$UXG]OP_Y]O[STO['_ +_X'\_%%?T#_P#"I_!/_0IZ!_X+H?\
MXFC_ (5/X)_Z%/0/_!=#_P#$T?V_#_GV_O#^Q_[_ .!_/SBBOZ!O^%3^"?\
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MS_@H7_R>'X^_[AW_ *;[>OG.OT_ _P"[T_\ "C\_Q/\ 'GZL7^&BOV0_8?\
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MYI=;'V&!EST("T445Y)Z!P7QR_Y(=\0O^Q>O_P#TF>OP$K]^_CE_R0[XA?\
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MB\W_ *4PU^JU?(YQ_O;]$?19?_NL/G^84445XIZ@5^*7_!0K_D\3Q]_W#O\
MT@MZ_:VOQ2_X*%?\GB>/O^X=_P"D%O7T61_[Q/\ PO\ -'B9M_ ^?Z'SK7[8
M_L%?\FD_#W_KWF_]*YJ_$ZOV0_8?^('A?1?V6_ EG?>)=*LKN*WFWP75]&CI
M_I,W8G->QGBO0A;N>=D[M4GZ'U/17'?\+8\$_P#0V:!_X,8?_BJ/^%L>"?\
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M/5=CW\#C?;>Y4^(^J****^?/8"OSN_X*[_\ (#^&7_7Q?_\ H,%?HC7YW?\
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M (*Y?\B'\/?^PC<?^BA7JY7_ +W#Y_D<.-_@3]#\R*_1O_@C_P!?BW]-(_\
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MPB7B*[V>#->F78[_ '+"\;A9?9'^ZWMM/8U^OM?SCU^M'_!/']J3_A;/@O\
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MPZ@^+?\ T,'@O_P.N_\ Y%H_M+!_SH/J>(_D9\6T5]I?\.G_ (M_]#!X+_\
M Z[_ /D6N4^(W_!.'XP?#_P_/JT=OI7B>W@1GF@T.ZDEF15_V)(T+_10351S
M#"3TYT'U/$?R,^?OA_\ #G7/B9K\>B^'X(+K4)?N03WT%OO_ ._C**_2[]CW
M_@GXOPAURW\:>.KN#4?$L'SV.FVOSV]DW_/1G_Y:2?3Y5]^"/RLK[2_8=_;9
MUSP#XNTWP/XTU*?5/!^I2K:6EU=/OETR5N$(8_\ ++/!4\+U'<'FS*G7G0O0
M^?F=. J4(5/WFY^LM%%%?GI]D%%%% 'Y,_\ !6#_ ).(\/\ _8JVW_I7=U\6
MU]I?\%8/^3B/#_\ V*MM_P"E=W7Q;7Z3EG^Z0]#X/&_QY^H4HXKW_P""O[$O
MQ#^/7@N/Q3X9DT=-,::2W_TZZ9'W)UX"'UKOS_P2Z^,_]_PY_P"#%O\ XW6D
ML9AX^Y4FDUYBCA<1+:#LSY HKZ^_X=<_&?\ O^'?_!BW_P ;H_X=<_&?^_X=
M_P#!BW_QNI^O8/\ G7WE?4\1_(SY"K]>?^"8AQ^R_!_V&;S^E?(G_#KGXS_W
M_#G_ (,6_P#C=?>W[%OP9\0? GX+IX6\3?97U-;Z:X_T&3>FU\ <X'I7C9MB
ML/5H<E.:;NMCULNP]2E7YZD+*Q]!T445\:?2A1110 4444 ?BG_P4+_Y/#\?
M?]P[_P!-]O7SG7T9_P %"_\ D\/Q]_W#O_3?;U\YU^GX'_=Z?^%?H?G^)_CS
M]6?I'^RW^WE\,/A+\"?"?A/7I]535M-BD2X\BRWI\T[OUR.S5ZQ_P\\^"G_/
M?Q!_X*__ *]?D*._%)7!5R:A.?/K=ZO4[XYI7A[FFA^O?_#SSX*?\]_$'_@K
M_P#KT?\ #SSX*?\ /?Q!_P""O_Z]?D)167]B87S^\O\ M:OY?<?KW_P\\^"G
M_/?Q!_X*_P#Z]-F_X*@?!=8]ROK\_P#TS_LY?_BJ_(:BG_8F%\_O#^UJ_E]Q
M]3_MI_MEQ?M+/I.BZ'IMUI?A?2YFN4^W;?-N9=NT,RKD+A<XY/WC7RQ2FK&G
MZ?<ZO?06-C!/>W=PZQ100)O=V;L *]>A1IX:GR0T2/-J5*F)GSSW9]X?\$D]
M-EF\>>/[X1_Z/%ID$+R?[3R$K_Z+:OT_]Z^8?V$?V=[GX!_!W_B=P;/%&O3?
M;KZ#_GBNW$4/U49)_P!IFKZ=]17Y[F595L5.<-C[+!T_8T(0GN+1117G'<<%
M\<O^2'?$+_L7K_\ ])GK\!*_?OXY?\D.^(7_ &+U_P#^DSU^ E?99!\%3U1\
MQG'_ "[^9Z-^S?\ \G$?"O\ [&K2O_2N.OWRK\#?V;_^3B/A7_V-6E?^E<=?
MOE7'GG\6'I^ITY3_  Y^H4445\R>\%%%% !1110 4444 %%%% !69J6I6NBV
M,]]>21VMI;HTLT\GR(BKR2:TZ^'_ /@II\>CX!^&D'@'2[C9K7BC=]K\O[Z:
M>OWA_P!M&^3Z"0=ZVPU'ZQ4A3AU,*]3V-/G['Y^?M.?&JZ^/GQBUWQ5)YB:>
MS_9-.@D_Y8VJ<1CZG[Y]V-<S\(_AKJ?Q>^)7A[P?I/\ Q]:I<+#O_P">,762
M4^RIN;\*Y&OTG_X)7_ W[#H^L_%+4H/](O-VF:3O_P">2_ZZ4?5\)_P!O6OT
M/%5*>!P_N=%9'R&'C];Q'O\ 4^[?!?@_3/ /A72?#NCP?9=,TNWCM+>/_91<
M"NCHHK\WO=W9]L%?D9_P4L^!/_"N?B\GC338-FB>+=TLWE_<AOE_UH_X'_K/
M<E_2OUSZ5Y%^TU\%[;X\?!K7?";>6E\R?:-.GD_Y8W2<QGZ'[I]F->CE^)^J
M5^?H]&<.+H_6*?)U/PES7Z__ /!._P"/W_"W/@['H.I3^?XE\+[;2X\S[\UM
M_P L9?P V'W4'O7Y$W^GW.D7UQ8WD#P7=K*T,L$GWT96P0?I7JO[*_QPG_9_
M^,VB^)/,D_L=O]$U:"/_ );6S_>_[X.''NM?:YEA_KF'OU6J/F,!6^K5[='H
MS]V:*SK.^@U:UCNK62.>WE17ADC^='5NAK1K\X/M0HHHH *^$O\ @K5_R2#P
MA_V'&_\ 1$E?=M?"7_!6K_DD'A#_ +#C?^B)*]/+?][AZG#C?X$_0_+2OU>_
MX)/_ /)O?B'_ +&JX_\ 22TK\H:_5[_@D_\ \F]^(?\ L:KC_P!)+2OJ\[_W
M7YH^9RK^/\F?;5?'O[:O[%-E\=M+G\5>%8(=/\?6<7^Y%JT2_P#+*3_II_=?
MO]T\8*_85%?#T*]3#U/:4]&CZ^I3A6AR3U3/YTM6TN\T34KO3]0M)[*]M96A
MF@G38Z,O4$58\.^(M3\(:Y8ZQH]]/IVI6<RS6]U ^QT9:_6K]LS]B/3/CY8R
M>)O#?EZ7X]MX?]9]R+4U7I')Z/\ W7_ \<C\D=<T/4/#.L7>DZM:3Z=J%G,T
M-Q:SIL=&7L:_0<%BZ>,IV>_5'QN(PU3!U+K;HS]@?V-?VRM,_:)T./1]8D@T
M[QU9Q?Z78_<2\5?^6T7_ +,O\/TZ?5%?SM>'?$6I^$=<L=8T>^GT[4[.99K>
MZ@?8Z,M?KQ^QW^VAI'[0VCP:'K4D&E^/;6+]]8_<BO%7_EM#[]RG4?3D?-YE
MEOL?W]#X>J['O8+'^V_=U/B/JVOSN_X*[_\ (#^&7_7Q?_\ H,%?HC7YW?\
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M_DAWQ"_[%Z__ /29Z_ 2OLL@^"IZH^8SC_EW\ST;]F__ ).(^%?_ &-6E?\
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M-*^'O_7O-_Z5RU]#5\)B<77C7G:;M=]?,^RIX>@X0]Q;+H?*[?\ !-?X%_\
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M]U5QS^]ZGK7Q\U%>[7PU+$_Q-;'BT:U2C\&ES[B_X>S_ !)_Z%3PK_WQ<_\
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M_P#>/DOU/4RO^!\V%%%%> >N%%%% !113))-E 'SY^W1X^B^'?[+_C.;S/\
M2-4M_P"R84_OM<?NV_\ '/,/X5^)U?7G_!0W]IRT^,WCBT\)^&[O[5X4\/NS
MO/&_R7EXW!D'JB+\JGW?U%?(?O7Z#E&&^KT/WF\CXS,ZWMJ_DCW;]A[PNWB[
M]J?P#;?\LK6[:^=_[GDQ/*/_ !Y0*_<&OS0_X)._"N275O%GQ$NH/W4$*Z38
MR?WV;$D_Y 1#_@1K]+^]?-YQ5Y\1R?RJQ[F64^2AZA1117A'KA1110 4444
M%%%% !1110 4444 %>7?'328KS1])O+B/?;Q7?V:X_ZY3*8_T?RS7J-8?C+0
M4\4>%=2TO[CW4+)%)_<E_@;\&PU ')?#/QY)>2?\(WKDG_$[MT_T>Z?_ )B$
M2_\ +0?[8_C7_@70\>DU\R>9_P )#HUI--Y]E=Q?/O@?9+;3I\K;6_A=7W+7
M=^#OC-]C>#2_%SI;7#.J6VL?<M[K_KI_SR?_ ,=/8CI0![!13%998]R_.C4^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV/Z&O^$NT/\ Z#5C_P!_X_\ &C_A+M#_ .@U8_\ ?^/_ !K^>2BOG_[ _O\
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M *U>UEN8?5*G)/X6>9C<$L1"_P!I'X;PS2P3QR1R21S*^])(_OHU?J/^PO\
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M.RWZY4]ISVMY'%A,?]4^Q>_F?T,_\)=H?_0:L?\ O_'_ (T?\)=H?_0:L?\
MO_'_ (U_/)17G?V!_?\ P/0_MG^Y^)_0W_PEVA_]!JQ_[_Q_XT?\)=H?_0:L
M?^_\?^-?SR44?V!_?_ /[9_N?B?T-_\ "7:'_P!!JQ_[_P ?^-'_  EVA_\
M0:L?^_\ '_C7\\E%']@?W_P#^V?[GXG]#]KXBTJ\G\FWU*UGE_YYP3J[_E6Q
MUXK\4_\ @GG_ ,GA^ ?^XC_Z07-?M;7SV-PGU.I[/>ZN>OA,3]9I\^UF)GI7
M/>+O%6F^"/#FI:]K$_V73].MY+NXG_N1(N3715^>7_!4KX^+8Z/IOPKTF?\
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M'7+"?3M5LY?)N+6;[Z-_AZ'O7Z#@L=3QD.S6Z/C<7A)X:?D9%?K;_P $L?\
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M-)UI:_/I2=1\\]6]3[&$.1!1112&%%%% !1110 4444 %%%% !1110 4444
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MTN:Z>X^US^5]]8\8S_NU]A[J6MJ%:>'J>TANC*I3]M#DGLS\</\ AVC\</\
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MI'_C7['TG/X5Z.$S"O@X<D+6.&MA(8GX^A^.'_#L_P".'_0)TK_P:1_XT?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHZ /JS]BO_D$^+/^ON'_ -%O7TK7S5^Q7_R"?%G_ %]P_P#HMZ^E: "BBB@
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MW_P6*=#_ -M&RWT"5]=UX^95O;5^1;1T-:,>2'J%%%%>2=(4444 %<=\6/\
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MK_O<_D=>7_[K#Y_F%%%%>.>B%%%%  1FCWHSBOGG]L[]H!?@!\&[[4K.2/\
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MKU[U[Y7;7S#V/[O"VC%:7MN<M+!\W[RO[S['Q>O_  2O^#RP>7_:?BUV_O\
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M/GGJSJITX4O@T"BBBN<U"BBB@#\J?^"L_P#R6SPI_P!BZO\ Z4S5^A'[-?\
MR;S\*_\ L5=*_P#22.OSW_X*S?\ );/"G_8NK_Z4S5^A'[-?_)O/PK_[%72O
M_22.O=Q?^Y4/F>-A_P#?:GR/3J***\(]D^0O^"GG_)K]Q_V&;+^M<=_P26_Y
M)!XP_P"PXO\ Z(CKL?\ @IY_R:_<?]AFR_K7'?\ !);_ ))!XP_[#B_^B(Z^
MAC_R*I_XO\CR)?[]\C[NHHHKYX]<**** /#_ -JC]G>+]ICP+IGA>;77T%;7
M4X]3\^.#S=^V.:/9C(_YZGO7R]_PZ)TSO\3;K_P3K_\ 'J_1&BNRCC*^'AR0
MG9>B.2IA:-6?/.-V?F-\3O\ @E[IGP[^&OBCQ0OQ"NKYM$TNZU'[+_9:IYWD
MQ-)MSYW&=OI7SK^R+^S;!^TUXXU;0)M=?05L-.^U^?'!YN_]XB;<;A_>]:_7
M7]I;_DWGXI_]BKJO_I))7Y[_ /!)KGXV>*\?]"\W_I3#7OX?'5Y86I.<M5ML
M>36P]&.*A#DT=ST7_AT/IG_13;K_ ,%"_P#QZMWP!_P2]L?AYXZ\-^*8?B%=
M7LNB:C;ZFEJ^EJGG>3(L@7/FG&=N,X.*^]**\>698J:LY_@CU(X.C#[ 4445
MYAVA1110 5^+?Q@_Y/\ ]2_['6W_ /1\=?M)7XM_%_\ Y/\ ]2_['6W_ /1\
M=>]E'\2?^$\G,?@A_B1^TE%%%>">L%%%% !FD89%+7BG[6'QF;X&_ OQ#XFM
M_+_M78MIIT<G_/S+PI_X",O_ ,!JJ4?;5.2&[(G+D7/T1Y+^UY^WMI'P)FG\
M*^%8(->\:[/WWF?\>^G[O^>F/O/_ + Z=\=*^3_!?P+^/W[<$Z>(O%'B&>U\
M-2OOBOM8=DM]O?[+:IA3]0%7C&[-8O[#/[/?_#2GQ>U+7/%GF:CX<T9UN]1\
M_P"?[;=.Q*1,>X/S,WL,<;J_8*UM8+*TCM[>-$MU38D<?W$6OHJU2GEG[BC9
MSZMGDTXU,=^\GI'HD?$'AG_@D_\ #RP@_P")]XL\1ZO<?].OD6D7_?)5V_\
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MO6NG^./$W_(4^(M]:I_'!H>G06__ (^P=J7L.7XYI!S'T S;?F:O/_$WQT\
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M_??<^7._=TX]*_<.OQAT/_E(X_\ V4NX_P#2]Z_9[O73F[YYTW_=,,L^"?\
MB84445\^>R%%%% !7Y]?\%0/VA/[#\/VGPKT6X_TW5-MWK+Q_P %LK?NX?\
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M_P#8._\ :J48C$>TQ5.G#X8-)?>51H\M"=2?Q239\@_\$BO^1J^(O_7I9?\
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MAHLG^CWD6R:#?\]M.OWXF]U/YCGO7HQ&:\"<>1N$]&CU82YUH%%%%(L****
M"BBB@ HHHH _/[_@KC_R(OP^]/[1N/\ T4*^?_V>]'_:KO/AA82?"E[O_A#/
M-F^S>7=:=$F[S/WG$S!_OU] ?\%<O^1$^'W_ &$;C_T4*]9_X)L?\FH>'O\
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MZ5]%'_D5>LO\CR)?[]\C[CHHHKYT]<**** "BBB@#S']I3_DWGXJ?]BKJO\
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MU^H]>5_%W]GKP'\<M'GM?%GAZWO;ADV1:E'&J7L/^Y-C</H<CU%>I]?H5O\
M>J*?FCB^J5*/\";]&9/P'_:D\ ?M"6,DGA74I(]3B3?<:/?)Y5W"OKMY##_:
M4D5[0>%-?A1>+K7[)?[2TZV-_))>^%=6_P!>GR?:8/1O:2(\CT:OW7^\,5SY
MAA(8?DG3UC+5&N%Q'ME[^DHNS'4445Y1Z 4444 %%%% !1110 4444 %%%%
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M<"MSGBN;%8B&(TIP44MCHHT9T?CGS-[A1117$=04444 ?G]_P5R_Y$3X??\
M81N/_10K%_8O_;0^%WP;^ NC>%_%&M75CJUK<7$KQP6,DJ;7E9E^91CI7V?\
M6/@+X%^.MI86?C;1?[:M[!VEMX_M4]OL9EP?]4Z_KZ5YO_P[T_9]_P"B??\
ME;O_ /X_7MT\7A987V%?FT?2W^9Y52A7]O[:G;56U,S_ (>4? K_ *&&^_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R"_X*;?\G22?]@:T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y!?\%-O^3I)/^P-:_\
MH4E?..FU]'?\%-O^3I)/^P-:_P#H4E?._A^SGU*Z@M;6"2ZN[AU2&"!-[NS=
ME ZU^E833"0]$?'UO]XGZG6:376:7)NG2WCCDGN&^Y! C/*_T4<U]-? /_@G
MGK&N06^L?$R[DT2T;:Z:'8R?Z0__ %UE_P"6?^ZF3_M"OMKP'\(?!WPML?L_
MA?P]8Z6O\<D"?O7_ -Z0Y8_B:\;$YI0A\'O,]NA1GZ'P!X*_9L^*GBKRVM?!
M<FG1?\]]?F6R3_O@[I?R2O;_  O^Q#XA;RY->\9VMDG_ #PT>QWO_P!_)2!_
MY#-?9-%>%4S*O/LCNC3/"-!_8_\  &D^6VI07WBB7_J,7S.G_?M<)^E>N>'?
M"^D>%['[+H^FV.EVG_/"Q@6)/R4"MO-&:\^56<_CNS7E"BBBLR@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\@O\ @IK_ ,G23_\ 8&M?
M_0GKZQ_8-_91MOA?X5M/''B:TC?QEJD.^W23_F'P-T7V=A][V^7UK@/C-\(X
MOC#_ ,%'M"TN\@\_2K/1K?5+N/\ @\J+?A/Q? K]"UZ5]%B\6X86G0AU2;/(
MP^'_ '\Z_GH%%%%?.GKA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'CWA/X>SV?[2'CKQI=6^R&ZTG3M,L9_[ZKYCR
M_DPCKV&BBM)2Y_DDB8Q"BBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
